An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A recent story warns that some people with eating disorders, especially anorexia, are being put at risk because telehealth systems let them get GLP-1 weight-loss drugs without proper checks. The piece says doctors working through online clinics sometimes prescribe these powerful medications without enough in-person evaluation, and that can be dangerous for patients whose health is already fragile. GLP-1 drugs are a class of medicines that include names you might have heard, like semaglutide (the active ingredient in medicines such as Ozempic and Wegovy). They work by copying a hormone your gut releases after you eat. That hormone tells the brain you’re fuller sooner and slows how fast your stomach empties, which reduces appetite and can lead to weight loss. They were developed for diabetes and have become popular for weight loss. The article’s concern is not about a new clinical trial—it's about how these drugs are being prescribed in the real world. It reports that some people with anorexia are getting prescriptions through telehealth services that don’t do thorough physical exams or screen properly for eating disorders. The result can be severe because people with anorexia already have very low body weight, heart problems, or electrolyte imbalances; adding a medicine that further suppresses appetite or causes nausea could worsen those conditions. The piece cites examples and expert warnings rather than new experimental data, so it’s highlighting a pattern and danger rather than presenting measured outcomes from a controlled study. This matters because telehealth is convenient and expanding fast, and GLP-1 drugs are in high demand. Patients who need careful monitoring—those with a history of eating disorders, unstable medical conditions, or very low body weight—are the ones most likely to be harmed if screening and follow-up are lax. For friends or family members concerned about someone seeking weight-loss drugs online, this story underlines the importance of insisting on thorough medical evaluation, including physical exams and mental-health screening, and ongoing monitoring after a prescription is started. There are important caveats. The article flags risks and real-world prescribing practices but doesn’t provide new clinical trial evidence that telehealth prescriptions directly caused specific medical emergencies in large numbers. It’s also possible that many telehealth clinics do perform appropriate checks. People with eating disorders or serious medical conditions should not stop prescribed medication on their own; instead, they should talk to a trusted clinician. Regulators and professional groups are still catching up with how best to oversee telemedicine prescribing for high-impact drugs, so rules and practices may change. Bottom line: GLP-1 drugs can be helpful but also risky for people with eating disorders, and getting them through telehealth without proper screening could put vulnerable patients in danger.
Source: Latin Times